Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
Launched by GALDERMA R&D · Jun 25, 2010
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
The range of fillers tested in this study includes 5 different hyaluronic acid dermal fillers: Emervel Touch, Emervel Classic, Emervel Deep, Emervel Volume and Emervel Lips.
The study will last 6 month.
Injections will be performed at baseline. If necessary, the investigator will perform touch-up injections at the following visit (3 weeks later).
Investigator and subject satisfaction will be collected through questionnaires.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Seeking tissue augmentation treatment on the face,
- • Presenting a score of 3 (Moderately deep wrinkle)or 4 (Deep wrinkle) on the Lemperle Rating Scale (LRS) of both nasolabial folds.
- Exclusion Criteria:
- • At risk in term of precautions, warnings and contra-indication referred in the package insert of the study devices,
- • Who underwent previous injection of permanent filler in the injected area.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arras, , France
Nice, , France
Paris, , France
Berlin, , Germany
Darmstadt, , Germany
Patients applied
Trial Officials
Philippe KESTEMONT
Principal Investigator
Investigational site Nice France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials